Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts.
Ziani L, Chouaib S, Thiery J. · 2018
Read Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. by Ziani L, Chouaib S, Thiery J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5837994.txt.
Introduction
Ziani, Chouaib, and Thiery review how cancer-associated fibroblasts blunt the immune attack on tumors. Their review appeared in Frontiers in Immunology. These activated fibroblasts fill the stroma around cancer cells. They already had blame for growth, spread, and drug resistance.
The review adds immune sabotage to the charge sheet. Fibroblasts smother killer T cells and natural killer cells. They lure in suppressor cells that calm the response. Their secretions and stiff matrix work as indirect shields too. Striking the fibroblasts, or their signals, might free immunotherapy to work. Some settings hint they can also restrain tumors, a caution for blunt attacks.
Catalog record
| CREATOR | Ziani L, Chouaib S, Thiery J. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts By Linda Ziani, Salem Chouaib, Jerome Thiery Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2018.00414 ABSTRACT Abstract Among cells present in the tumor microenvironment, activated fibroblasts termed cancer-associated fibroblasts (CAFs), play a critical role in the complex process of tumor-stroma interaction. CAFs, one of the prominent stromal cell populations in most types of human carcinomas, have been involved in tumor growth, angiogenesis, cancer stemness, extracellular matrix remodeling, tissue invasion, metastasis, and even chemoresistance. During the past decade, these activated tumor-associated fibroblasts have also been involved in the modulation of the anti-tumor immune response on various levels. In this review, we describe our current understanding of how CAFs accomplish this task as well as their potential therapeutic implications. Keywords: cancer, tumor microenvironment, cancer-associated fibroblasts, immune suppression, immunotherapy INTRODUCTION It is now well admitted that tumor progression and metastasis formation do not only depend on cancer cell genetic and epigenetic defects but are also controlled by the tumor microenvironment (TME) (1, 2). The TME or stroma is composed of cells from endothelial, mesenchymal, and hematopoietic origins embedded in a complex extracellular matrix (ECM), which enter into a dynamic crosstalk with tumor cells, suitable for tumor growth. Consequently, different elements such as angiogenesis, hypoxia, ECM remodeling, interstitial pressure, metabolism changes have received recent attention as key determinants of the TME modifying cancer cell behavior and disease progression, with potential clinical applications (2, 3). Moreover, the TME is also clearly involved in shaping the cellular fate of tumor-infiltrating lymphocytes and the efficacy of the anti-tumor immune response. Indeed, during tumor progression, tumor cells proliferate under adverse host conditions and use several survival strategies to block the action of key regulators/effectors of the immune response and to circumvent anti-tumor defenses (4–6). Besides the several known classical strategies used by tumor cells to escape immune surveillance (such as down regulation of antigen expression, resistance to cell-mediated lysis or expression/secretion of immunosuppressive molecules), it should be noted that tumor cell evasion from immunosurveillance is also under the control of the TME complexity (7–9). The ability of tumors to orchestrate an immunosuppressive microenvironment is dependent on several mechanisms ultimately leading to the inhibition of various immune effector cells [such as cytotoxic T cell (CTL) or natural killer (NK) cells] or to the recruitment and stimulation in the TME of immunosuppressive cells [such as regulatory T cells (Tregs), type II macrophages or myeloid-derived suppressor cells (MDSCs)]. In particular, among the stromal cells, activated fibroblasts that share similarities with fibroblasts stimulated by acute or chronic inflammatory signals, activated during a wound healing process and observed during tissue fibrosis, also known as myofibroblasts, play a critical role in the complex process of tumor cell-stroma interaction (10–13) and have emerged as important regulators of the anti-tumor immune response (14–16). Here, we will discuss the different mechanisms involved in the immuno-suppressive capabilities of activated fibroblasts in the TME, as well as their potential application for therapeutic intervention, especially in the field of cancer immunotherapy. ORIGIN OF ACTIVATED FIBROBLASTS IN THE TME AND ROLE IN CANCER PROGRESSION Fibroblasts are spindle-shaped, non epithelial (cytokeratin−, E-cadherin−), non endothelial (CD31−) and non-immune (CD45−) cells of a mesenchymal lineage origin (vimentin+). In normal tissue, fibroblasts are usually considered as resting/quiescent cells with negligible metabolic and transcriptional activities (11), but with the ability to respond to growth factors to become activated. During this activation process, fibroblasts exhibit contractile activity, exert physical forces to modify tissue architecture, acquire proliferation and migration properties and become transcriptionally active leading to the secretion of several factors (cytokines, chemokines, etc.) and ECM components (17–19). The ability of resting fibroblasts to become activated was first observed in the context of wound healing (20) and subsequently in pathologic conditions such as acute or chronic inflammation or tissue fibrosis (a chronic wound healing response) (17, 21). This chronic tissue repair response also occurs in the context of cancer, considered as a “wound that never heals” (22). Indeed, emergence and/or accumulation of cancer cells in a given tissue represent a tissue injury, imitating a chronic wound healing response toward the tumor cells, also known as tumor fibrosis or desmoplastic reaction (23). Consequently, major players in tumor fibrotic microenvironment include activated fibroblasts, termed cancer-associated fibroblasts (CAFs), which represent one of the most abundant stromal cell types of several carcinomas including breast, prostate, pancreatic, esophageal, and colon cancers while CAFs are less abundant, but still present, in other neoplasias including ovarian, melanoma, or renal tumors (24). For example, in pancreatic cancer, 60–70% of the tumor tissue is composed of a desmoplastic stroma characterized by extensive collagen deposition and activated CAFs (25). Several studies have clearly demonstrated that cancer cells can recruit and activate tissue resident fibroblasts in the stroma (26, 27). This phenomenon is mainly dependent on growth factors released by the cancer cells and also by infiltrating immune cells. In particular, transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF) secreted by tumor cells are key determinants of fibroblast activation and proliferation within the TME (28–31). Moreover, the secretion of interleukin (IL)-1β (IL-1β) by immune cells in early neoplasia has emerged as an initiator of nuclear factor-κB signaling in fibroblasts involved in their education and production of pro-tumorogenic and pro-inflammatory factors (32). Furthermore, emerging data suggest that the irreversible activation of CAFs might be driven by epigenetic alterations (33–36). Nevertheless, CAFs can also originate from other cell populations than resident fibroblasts through different mechanisms and depending on the tissue analyzed. Several other local sources of CAFs have been thus suggested. In breast, kidney, lung, and liver carcinomas, a portion of CAFs have been shown to potentially differentiate from epithelial cells via an epithelial-to-mesenchymal transition (EMT) (37, 38). A related process, termed endothelial-to-mesenchymal transition has been involved in the trans-differentiation of endothelial cells to a cell population with a CAF-like phenotype (39). Other cells linked to blood vessels, named pericytes, can trans-differentiate into CAFs in a PDGF-dependent manner (40). Moreover, in breast cancer, adipocytes were shown to differentiate in CAFs (41, 42). Finally, in liver and pancreas tumors, stellate cells, normally involved in organ regeneration, are involved in fibrosis preceding the occurrence of tumors, making them a possible source of CAFs (43, 44). Beyond these local sources, more distant one can be involved in CAFs recruitment/differentiation in the TME. In particular, mesenchymal stem cells, normally residing in the bone marrow, can be attracted in the TME to become an important source of CAFs (42, 45–48). Similarly, fibrocytes, a circulating mesenchymal cell population arising from monocytes precursors which are recruited to sites of chronic inflammation, can differentiate into CAFs after their recruitment into the TME (46, 49). These various sources represent an important determinant that contributes to the heterogeneity of CAFs (Figure 1) and makes them difficult to distinguish from other cell types present in TME. In this context, morphology and spatial distribution are key determinants in order to identify fibroblasts in a resting or activated state (11). Different markers, which are lower or not expressed by their normal counterparts, can also be used to identify activated fibroblasts such as α-smooth muscle actin (α-SMA), fibroblast-specific protein-1 (FSP-1; also called S100A4), fibroblast-activation protein (FAP), PDGF receptors